In the last trading session, 2.94 million shares of the Akebia Therapeutics Inc. (NASDAQ:AKBA) were traded, and its beta was 0.91. Most recently the company’s share price was $1.36, and it changed around -$0.03 or -2.16% from the last close, which brings the market valuation of the company to $284.74M. AKBA currently trades at a discount to its 52-week high of $2.48, offering almost -82.35% off that amount. The share price’s 52-week low was $0.59, which indicates that the current value has risen by an impressive 56.62% since then. We note from Akebia Therapeutics Inc.’s average daily trading volume that its 3-month average coming to 4.80 million.
Akebia Therapeutics Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended AKBA as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Akebia Therapeutics Inc. is expected to report earnings per share of $Ambarella, Inc. for the current quarter.
Akebia Therapeutics Inc. (NASDAQ:AKBA) trade information
Instantly AKBA has showed a red trend with a performance of -2.16% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently up 9.68% year-to-date, but still down -6.85% over the last five days. On the other hand, Akebia Therapeutics Inc. (NASDAQ:AKBA) is -29.90% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $6.5, which translates to bulls needing to increase their stock price by 79.08% from its current value. Analyst projections state that AKBA is forecast to be at a low of $6 and a high of $7.
Akebia Therapeutics Inc. (AKBA) estimates and forecasts
Akebia Therapeutics Inc. share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 56.90 percent over the past six months and at a 0.00% annual growth rate that is well below the industry average of 10.20%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 35.46%.
AKBA Dividends
Akebia Therapeutics Inc.’s next quarterly earnings report is expected to be released in May.
